$14.16
2.58%
Nasdaq, Nov 19, 03:59 pm EST. Closed.
ISIN
US8036071004
Symbol
SRPT

Sarepta Therapeutics, Inc. Stock price

$14.17
-3.56 20.08% 1M
-2.47 14.84% 6M
-7.35 34.15% YTD
-2.22 13.54% 1Y
-68.89 82.94% 3Y
-65.84 82.29% 5Y
-23.46 62.34% 10Y
-8.63 37.85% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-0.36 2.48%

AI Insights on Sarepta Therapeutics, Inc. Insights AI Insights on Sarepta Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Sarepta Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.5b
Net debt
positive
Cash
$878.8m
Shares outstanding
107.2m
Valuation
P/E
109.0
P/S | estimate
0.8 | 0.8
EV/Sales | estimate
0.8 | 0.8
EV/FCF | ex SBC
8.7 | 24.4
P/B
1.0
Financial Health
Equity Ratio
34.1%
Return on Equity
-62.6%
ROCE
6.3%
ROIC
3.1%
Debt/Equity
0.6
Share-Based Compensation & Dilution
SBC | % of Revenue
$110.6m | 5.7%
SBC as % of FCF
64.3%
SBC Growth 1Y
-22.7%
Share Count Growth 1Y
2.3%
Shareholder Yield
-2.3%
Financials
Revenue | estimate
$2.0b | $1.9b
EBITDA
$159.7m
EBIT
$156.9m
Net Income
$14.8m
Free Cash Flow | ex SBC
$172.1m | $61.4m
Growth
Revenue | estimate
-19.0% | -13.5%
EBITDA
291.3%
EBIT
282.4%
Net Income
105.4%
Free Cash Flow
144.3%
Margin
Gross
65.2%
EBITDA
8.2%
EBIT
8.0%
Net
0.8%
Free Cash Flow | ex SBC
8.8% | 3.1%
More
EPS
$0.1
FCF per Share
$1.6
Short interest
21.5%
Employees
835
Rev per Employee
$2.6m

Sarepta Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

12x Buy
39%
13x Hold
42%
6x Sell
19%

Analyst Opinions

31 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

Buy
39%
Hold
42%
Sell
19%

Sarepta Therapeutics, Inc. Events

Past Events
NOV
5
Q3 2026 Earnings Call
15 days ago
SEP
14
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
AUG
5
Q2 2026 Earnings Call
4 months ago
JUN
8
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
JUN
4
Shareholder/Analyst Call - Sarepta Therapeutics, Inc.
6 months ago
MAY
6
Q1 2026 Earnings Call
7 months ago
MAR
25
Special Call - Sarepta Therapeutics, Inc.
8 months ago
MAR
3
TD Cowen 46th Annual Health Care Conference
9 months ago
FEB
25
Q4 2025 Earnings Call
9 months ago
JAN
26
Special Call - Sarepta Therapeutics, Inc.
10 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
NOV
3
Q3 2025 Earnings Call
about one year ago

Financial data from Sarepta Therapeutics, Inc.

Sep '26
+/-
%
1,956 1,956
19% 19%
100%
- Direct Costs 680 680
19% 19%
35%
1,276 1,276
31% 31%
65%
- Selling and Administrative Expenses 463 463
12% 12%
24%
- Research and Development Expense 653 653
53% 53%
33%
160 160
291% 291%
8%
- Depreciation and Amortization 2.80 2.80
10% 10%
0%
EBIT (Operating Income) EBIT 157 157
282% 282%
8%
Net Profit 15 15
105% 105%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Sarepta Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sarepta Therapeutics, Inc. Stock News

Neutral
Business Wire
●
14 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2026. “After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential...
Neutral
Business Wire
●
about one month ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) demonstrating that SRP-1003, the company's investigational small interfering RNA (siRNA) program for the treatment of myotonic dystrophy type 1 (D...
More Sarepta Therapeutics, Inc. News

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Head office United States
CEO Mr. Ingram
Employees 835
Founded 1980
Website www.sarepta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today